Old Web
English
Sign In
Acemap
>
authorDetail
>
David Gandara
David Gandara
University of California, Davis
Medicine
Pathology
Lung cancer
Cancer
Proteasome
4
Papers
90
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer
2005
Lung Cancer
Melinda M. Mortenson
Michael G. Schlieman
Subbulakshmi Virudachalam
Primo N. Lara
David Gandara
Angela M. Davies
Richard J. Bold
Show All
Source
Cite
Save
Citations (46)
Effects of the 26S proteasome inhibitor, bortezomib, on BCL-2 in small cell lung cancer: Implications for SWOG-0327
2004
Journal of Clinical Oncology
Melinda M. Mortenson
Michael G. Schlieman
Subbulakshmi Virudachalam
Primo N. Lara
David Gandara
Angela M. Davies
Richard J. Bold
Show All
Source
Cite
Save
Citations (2)
Twice-Weekly P aclitaxel a nd W eekly C arboplatin W ith Concurrent T horacic R adiation F ollowed b y C arboplatin/ Paclitaxel C onsolidation f or S tage I II N on-Small-Cell Lung C ancer: A C alifornia C ancer C onsortium P hase I I Trial
2001
Derick Lau
Bryan R. Leigh
David Gandara
Martin J. Edelman
Robert J. Morgan
Valerie Israel
Primo N. Lara
Richard B. Wilder
Janice Ryu
James Doroshow
Show All
Source
Cite
Save
Citations (0)
Predictors of survival following relapse or progression of small cell lung cancer : Southwest oncology group study 8605 report and analysis of recurrent disease data base
1993
Cancer
Kathy S. Albain
John Crowley
Laura Hutchins
David Gandara
Robert M O’Bryan
Daniel D. Von Hoff
Brian Griffin
Robert B. Livingston
Show All
Source
Cite
Save
Citations (42)
1